On January 21, 2020, Keith Murphy sent a letter to the shareholders of Organovo Holdings, Inc. In the letter, Keith Murphy stated that on December 16, 2019, the Company announced that its strategic alternatives review had identified Tarveda Therapeutics as its chosen merger partner. Keith Murphy stated that Tarveda Therapeutics is a mismatch with the Company's shareholder base that would leave investors running for the exits. Keith Murphy added that Tarveda Therapeutics is a company with a technology so unexciting to its own previous investors that it has not been able to raise additional VC funding or execute an IPO in a bull biotech market and is now seeking other financing options. Keith Murphy stated that, because of the problems with Tarveda Therapeutics, the Company stockholders must prepare to vote against Tarveda Therapeutics merger and force the Company's Board to go back to the beginning of the process and deliver what the shareholders demand: a deal that makes use of the Company's unique bioprinting technology, not a deal that bails out the VC investors of a failing cancer drug company.